PLURNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30

Pluri Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 10, 2026

$0.85−0.08 (-8.58%)

Close on Oct 19, 2026

Market cap: $9.08M
P/E (TTM): –
Dividend yield: –

Pluri Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2014 2014-06-30	FY 2013 2013-06-30	FY 2012 2012-06-30	FY 2011 2011-06-30	FY 2010 2010-06-30
Depreciation & Amortization	0.51	0.32	0.25	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Stock-Based Compensation	3.73	2.14	2.62	3.98	8.91	14	2.56	5.15	6.55	3.66	3.07	4.05	5.85	2.80	4.93	–	–
Deferred Income Taxes	-0.03	-0.01	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Cash Items	0.35	0.25	0.15	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Change in Accounts Receivable	0.15	-0.20	0.08	–	–	–	–	–	–	–	–	–	-0.14	-0.23	0.06	–	–
Change in Accounts Payable	-0.08	-0.24	-0.78	-0.02	-0.76	0.58	-0.29	-0.86	1.21	-0.70	-0.08	-0.57	1.26	1.34	-0.42	0.46	0.13
Change in Unearned Revenue	-0.08	0.11	–	–	–	–	–	–	–	–	-2.85	-0.38	-0.38	-0.68	4.28	–	–
Operating Cash Flow	-20	-18	-18	-23	-37	-31	-26	-29	-21	-22	-19	-21	-19	-17	-3.28	-5.76	-5.41
Capital Expenditures	-0.63	-1.62	-0.32	-0.26	-0.28	-0.37	-0.27	-0.24	-0.34	-0.38	-1.75	-0.83	-1.57	-4.31	-1.48	-0.96	-0.39
Acquisitions	–	–	–	–	–	-0.02	-0.04	–	–	–	–	–	–	–	–	–	–
Sale of Property, Plant & Equipment	0.02	–	–	–	–	–	–	–	–	0.03	0.03	0.02	–	–	–	0.03	–
Purchase of Investments	–	–	–	–	–	–	-12	-0.01	-1.15	-3.61	-4.22	-4.90	-11	-8.53	-1.13	-0.01	-0.01
Sale & Maturity of Investments	–	–	–	–	–	–	–	–	22	5.94	8.09	11	6.87	2.38	1.00	0.90	1.60
Investing Cash Flow	9.90	8.03	11	9.70	12	-7.27	-30	1.17	5.68	4.36	1.31	22	1.98	-20	-31	-0.04	-1.30
Stock Issued	5.07	9.58	0.09	8.02	–	37	58	23	19	16	0.79	17	11	34	–	43	5.95
Debt Repaid	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.02	-0.01
Other Financing Activities	–	–	–	–	–	–	–	0.11	0.09	0.07	–	–	–	–	–	–	–
Financing Cash Flow	7.04	9.53	8.84	8.02	7.50	61	61	24	20	16	0.81	17	13	36	0.63	47	5.95
Foreign Exchange Rate Adjustments	0.03	0.18	0.01	-0.02	-3.21	-0.13	–	–	–	–	–	–	–	–	–	–	–
Net Change in Cash	-2.62	-0.48	1.42	-5.16	-20	23	4.04	–	4.11	-1.52	-16	18	-4.51	-0.38	-33	41	-0.76
Free Cash Flow	-20	-20	-18	-23	-37	-31	-27	-30	-22	-22	-20	-21	-21	-21	-4.76	-6.72	-5.80
Income Taxes Paid	–	–	–	–	–	–	0.01	0.01	0.03	0.03	0.07	0.05	0.05	0.02	0.01	0.01	0.01
Interest Paid	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 44.6%
Operating margin: -2454.5%
Net margin: -2344.6%
Return on equity, FY2026: 159.5%

Financial strength

Current ratio: 0.27
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 10.8%

Valuation

P/E ratio: –
Price to sales: 8.94
Price to book: –
Dividend yield: –